Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is endorsed by the American Society for Preventive Cardiology, and supported by an educational grant from Amgen, Inc.

Protecting Our Patients From ASCVD: Optimizing the Use of Non-Statin Therapies

Release Date: October 29, 2021
Expiration Date: October 29, 2022

Activity Overview

Elevated cholesterol levels, including low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), cholesterol carried in LDL, intermediate density lipoprotein, lipoprotein(a), very low-density and remnant lipoprotein, are a root cause of atherosclerosis. Clinical trials have demonstrated that lowering elevated atherogenic cholesterol levels reduces the risk for heart attack and stroke. Statins are the cornerstone pharmacologic therapy for the management of hypercholesterolemia, but a relatively large segment of the population with hypercholesterolemia remains at residual CVD risk despite taking statins, indicating a need for new therapies. In recent years, novel non-statin therapies have become available for these patients. In 2015, two treatment modalities from a new class of lipid-lowering drugs, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), were approved for use by the FDA. And in February 2020, bempedoic acid and bempedoic acid/ezetimibe were Food and Drug Administration (FDA) approved as add-on treatments for patients taking a high dose of statins and still in need of additional LDL-C reduction.  
This continuing medical education (CME) activity assists clinicians in managing hypercholesterolemia in accordance with the latest clinical evidence and guidelines, with an emphasis on understanding unmet needs in statin therapy and the role of non-statin therapies. Moreover, given the rapid rate at which this field is evolving and the novel therapies being investigated, clinicians also need to be aware of emerging approaches so that they are confident about integrating new therapies into their clinical practice as they become available.

Acknowledgement of Commercial Support

This activity is endorsed by the American Society for Preventive Cardiology, and supported by an educational grant from Amgen, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward cardiologists, lipidologists, internists, NPs, PAs, and other HCPs who treat patients with dyslipidemia.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Apply guideline recommendations to individualize non-statin therapies for patients with hypercholesterolemia
  • Select individualized treatment utilizing non-statin therapies for patients with elevated LDL-C
  • Evaluate the efficacy and safety of current and emerging non-statin therapies for the management of patients with hypercholesterolemia

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies. 


Yelena Y. Janjigian, MD
President & Chief Medical Officer
Excel Medical Clinical Trials
Clinical Affiliate Professor of Cardiology
Department of Integrated Medical Science
Charles E. Schmidt College of Medicine, Florida Atlantic UniversityFAU
Boca Raton, FL

Disclosures: Consultant: Consultant: Sanofi Genzyme; Amgen Inc.; Regeneron Pharmaceuticals, Inc.; Akcea Therapeutics; Novartis Pharmaceuticals; Speakers’ Bureau: Amgen Inc.; Boehringer Ingelheim; Eli Lilly and Company; Esperion Therapeutics, Inc.; Regeneron Pharmaceuticals, Inc.

Maurice Pérol, MD
Pam R. Taub, MD
Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
Professor of Medicine
Division of Cardiovascular Medicine
UC San Diego Health System
La Jolla, CA

Disclosures: Consultant: Consultant: Amarin Corporation; Amgen Inc.; Bayer; Boehringer-Ingelheim; Esperion Therapeutics, Inc.; Medtronic; Novartis Pharmaceuticals; Novo Nordisk; Sanofi Genzyme; Stock/Shareholder: Epirium Bio

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By